The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Analysts expect Eli Lilly to report $12.1 billion in sales and $1.45 in adjusted earnings per share for the quarter. Eli ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

The study centered on those who struggled with their former therapy. Lilly claims that the findings revealed Ebglyss made notable progress, especially in challenging areas like the face and hands.

Lilly added that the study also showed Ebglyss was able to achieve meaningful improvements in patients with ...

Eli Lilly's EBGLYSS has demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe atopic dermatitis, according to new results from the Phase IIIb ADapt study.

EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity. 2,3,4 The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce itchiness in patients ...

New results show Eli Lilly’s (LLY) Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results from the ...

Total European sales in this segment grew by 21.9%, underscoring the company’s expanding ambition in the region. The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 ...